Flex Pharma

Flex Pharma is a biopharmaceutical company founded in 2014 in the United States. The company focuses on developing innovative treatments for neuromuscular disorders, specifically targeting muscle cramps. It has shown promising human efficacy in addressing muscle cramping through its novel approach. Unlike traditional remedies such as sports drinks and stretching, which are often ineffective, Flex Pharma's research indicates that muscle cramps and spasms are caused by neural mechanisms, specifically the excessive firing of motor neurons in the spinal cord. The company's products aim to halt this repetitive firing, offering relief from muscle cramps and spasms within minutes, with effects lasting for hours. The company's founders include esteemed professors from Harvard Medical School and Rockefeller University, and it has garnered significant attention from investors. Flex Pharma has received a $40.00M Venture Round investment from a consortium of renowned investors including Bessemer Venture Partners, Correlation Ventures, Spark Capital, Bindley Capital, City Hill Ventures, EcoR1 Capital, QVT Financial, CD-Venture, Jennison Associates, and Alexandria Real Estate Equities, demonstrating strong support and interest in the company's vision and potential. Overall, Flex Pharma's pioneering approach to addressing neuromuscular disorders, backed by a notable founding team and substantial investment, positions the company as a compelling player in the biotechnology and pharmaceutical industries.